Codiak BioSciences, Inc. CDAK shares rallied 18.2% in the last trading session to close at $6.62. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock’s 49.7% loss over the past four weeks.
The rise is most likely attributable to positive investor expectations on development of pipeline candidates targeting cancer indications using exosome based therapeutics.
This company is expected to post quarterly loss of $0.93 per share in its upcoming report, which represents a year-over-year change of +18.4%. Revenues are expected to be $4.54 million, up 177% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Codiak BioSciences, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock’s price usually doesn’t keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on CDAK going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here >>>>
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.3% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Click to get this free report
Codiak BioSciences, Inc. (CDAK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
www.nasdaq.com